Introduction: Hyperplastic changes of the endometrium constitute one of the most fundamental clinical problems of perimenopausal and postmenopausal women. The spectrum of pathological endometrial changes connected with proliferation includes endometrial polyps, endometrial hyperplasia and endometrial cancer. The connection between endometrial cancer and endometrial hyperplasia with type 2 diabetes and insulin resistance has been known for long.Study objective: Assessment of frequency of carbohydrate disorders as well as hormonal and receptor status in perimenopausal and postmenopausal women with hyperplastic changes of the endometrium; Comparison of the efficiency of treatment with insulin-sensitizing agents (metformin) and progestagens (lynestrenol) with the efficiency of treatment only with progestagens (lynestrenol) in women with endometrial hyperplasia.Material and methods: Group of 100 perimenopausal and postmenopausal patients who displayed abnormal uterine bleeding and/or thickened endometrium in transvaginal ultrasonography. The population of women under study was divided into four groups (non-atypical endometrial hyperplasia, endometrial polyp, endometrial cancer, control group). Patients with endometrial hyperplasia were randomly divided into 2 groups of patients depending on the administered treatment (progestagens + metformin vs only progestagens).Conclusions: Insul ; in resistance occurs in approximately half of the women with hyperplastic changes of the endometrium. Insulin level in the 120th minute of the OGTT is the best parameter in predicting endometrial hyperplasia. Androgens play a role in premenopausal women and estrogens in postmenopausal women with endometrial hyperplasia. IGFBP-3 may contribute to pathogenesis of endometrial hyperplasia. In all patients with endometrial hyperplasia, regardless of the implemented treatment, in the 6 month period regression ofhyperplastic changes occurred. In case of women with abnormal insulin resistance markers who experience pathological uterine bleeding and/or thickened endometrium, there is clinical basis for recommending modification of life style or for introduction of pharmaceutical insulin-sensitizing agents.
Mar 17, 2023
Mar 6, 2013
10
0
http://dl.cm-uj.krakow.pl:8080/publication/3425
Edition name | Date |
---|---|
ZB-115825 | Mar 17, 2023 |
Kacalska-Janssen, Olga
Radomska, Monika
Kiałka, Marta
Wanic, Krzysztof
Janczura, Mirosław
Cyganek, Katarzyna
Ożga, Katarzyna Maria
Niedbał, Sylwia